Andere talen Skye Bioscience, Inc.

Aandelen

EMBI

US83086J2006

Geschatte realtime Cboe BZX Andere beurzen 16:29:27 20-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
12,02 ^USD	-0,21%		+6,49%	+346,69%

10/05	Skye Bioscience, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
22/03	Skye Bioscience, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting	13/05
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index	23/04
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index	12/04
Skye Bioscience Uplists to The Nasdaq Global Market	10/04
SKYE BIOSCIENCE : AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS - Form 8-K	03/04
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Skye Bioscience, Inc. announced that it has received $40 million in funding	13/03
Skye Bioscience Announces $40 Million Private Placement Equity Financing	11/03
Skye Bioscience, Inc. announced that it expects to receive $40 million in funding	11/03
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors	04/03
Skye Bioscience Announces Board Changes	04/03
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	26/02
Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	26/02
Skye Bioscience, Inc. announced that it has received $49.99101 million in funding	12/02
Skye Bioscience to Present at Oppenheimer Investor Conference	07/02
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing	29/01
Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding	29/01
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease	09/01
Skye Bioscience Responds to OTC Markets Promotional Policy	11/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Skye Bioscience, Inc.

Aandelen

EMBI

US83086J2006

Andere talen

Filters